| Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. | |
| | |
MedLine Citation:
|
PMID: 20498620 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Telmisartan is a unique AT1 receptor blocker with a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonistic action. Activation of PPAR-gamma could prevent inflammation and brain damage. METHOD: We investigated the beneficial effect of telmisartan on ischemic brain damage via PPAR-gamma activation as well as AT1 receptor blockade. Eight-week-old male KK-Ay mice were subjected to middle cerebral artery occlusion. Before middle cerebral artery occlusion, they were administered telmisartan or losartan, with or without GW9662, a PPAR-gamma antagonist, for 2 weeks. Ischemic area, neurological score, oxidative stress, inflammation and cerebral blood flow were assessed 24 h after middle cerebral artery occlusion. RESULTS: Administration of telmisartan, losartan, GW9662 and these AT1 receptor blockers with GW9662 had no significant effect on blood pressure. KK-Ay mice exhibited a significant increase in the ischemic area compared with C57BL6 mice. Treatment with telmisartan decreased the ischemic area and improved the neurological score compared with the no-treatment group, with an increase in cerebral blood flow and a reduction in superoxide production and expression of inflammatory cytokines. These protective effects of telmisartan were partially attenuated by coadministration of GW9662, although GW9662 treatment alone had no significant effect on ischemic area. Losartan treatment showed a reduction in ischemic area compared with nontreated KK-Ay mice. However, coadministration of GW9662 had no effect on the losartan-mediated reduction in ischemic area. CONCLUSION: These results suggest that telmisartan has a beneficial effect on stroke partly due to activation of PPAR-gamma as well as AT1 receptor blockade. |
| | |
Authors:
|
Jun Iwanami; Masaki Mogi; Kana Tsukuda; Li-Juan Min; Akiko Sakata; Fei Jing; Masaru Iwai; Masatsugu Horiuchi |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of hypertension Volume: 28 ISSN: 1473-5598 ISO Abbreviation: J. Hypertens. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-21 Completed Date: 2010-11-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8306882 Medline TA: J Hypertens Country: England |
Other Details:
|
Languages: eng Pagination: 1730-7 Citation Subset: IM |
Affiliation:
|
Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
pharmacology* Anilides / pharmacology Animals Benzimidazoles / pharmacology* Benzoates / pharmacology* Blood Flow Velocity / drug effects Blood Pressure / drug effects Cerebral Cortex / blood supply, drug effects Cytokines / metabolism Diabetes Mellitus, Experimental / drug therapy*, metabolism, pathology Drug Antagonism Drug Therapy, Combination Infarction, Middle Cerebral Artery / metabolism, pathology, prevention & control* Losartan / pharmacology Male Mice Mice, Inbred C57BL PPAR gamma / antagonists & inhibitors, biosynthesis* Superoxides / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/2-chloro-5-nitrobenzanilide; 0/Angiotensin II Type 1 Receptor Blockers; 0/Anilides; 0/Benzimidazoles; 0/Benzoates; 0/Cytokines; 0/PPAR gamma; 11062-77-4/Superoxides; 114798-26-4/Losartan; 144701-48-4/telmisartan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of two instruments measuring carotid-femoral pulse wave velocity: Vicorder versus Sphygmo...
Next Document: Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Scor...